Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer

Clinical Cancer Research

Volumn 13, Issue 4, 2007, Pages 1208-1215

  Dreicer, Robert ^a   Petrylak, Daniel ^b   Agus, David ^c   Webb, Iain ^d   Roth, Bruce ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BORTEZOMIB; DEXAMETHASONE; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; PROTEASOME;

ACUTE HEART INFARCTION; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APPETITE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSGEUSIA; DYSPEPSIA; DYSPNEA; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; INSOMNIA; LACRIMATION; LEG EDEMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAIL DISEASE; NAUSEA; NEUROPATHY; OPTIMAL DRUG DOSE; PARESTHESIA; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; SENSORY NEUROPATHY; SIDE EFFECT; TREATMENT RESPONSE; URINE RETENTION; VOMITING; WEAKNESS;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGENS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRAZINES; TAXOIDS;

EID: 33947196412     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2046     Document Type: Article

References (48)

1. Petrylak D, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
2. Tannock I, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351: 1502-12.
3. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res 2004;64:5036-43.
4. Lindholm PF, Bub J, Kaul S, Shidham VB, Kajdacsy-Balla A. The role of constitutive NF-κB activity in PC-3 human prostate cancer cell invasive behavior. Clin Exp Metastasis 2000;18:471-9.
5. Sweeney C, Li L, Shanmugam R, et al. Nuclear factor-κB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 2004;10:5501-7.
6. Gustin JA, Maehama T, Dixon JE, Donner DB. The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor κB activity. J Biol Chem 2001;276:27740-4.
7. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ. Targeting BCL-2 overexpression in various human malignancies through NF-κB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 2005;56:46-54.
8. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002;7:9-16.
9. Cusack J. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 2003;29:21-31.
10. Scheffner M, Huibregtse JM, Howley PM. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci U S A 1994;91: 8797-801.
11. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-72.
12. Richardson P, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
13. Richardson P, Sonneveld P, Schuster M, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352: 2487-98.
14. Adams J, Palombella V, Sausville E, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
15. An J, Sun Y, Adams J, Fisher M, Belldegrun A, Rettig M. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) α, and TNF-related apoptosis-inducing ligand in prostate cancer. Urol Oncol 2003; 21:490-1.
16. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000;6:3719-28.
17. Ikezoe T, Yang Y, Saito T, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci 2004;95: 271-5.
18. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002;8:S49-54.
19. Cusack J, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 2001;61:3535-40.
20. Denlinger CE, Rundall BK, Keller MD, Jones DR. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 2004;78:1207-14.
21. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-44.
22. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
23. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 2004;54:343-53.
24. Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 2000; 60:2429-34.
25. Russo SM, Tepper JE, Baldwin AS, Jr., et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 2001;50:183-93.
26. Farneth N, Holland W, Kenosi T, et al. Proteasome inhibition with bortezomib in combination with docetaxel in prostate cancer cells and xenografts [abstract 3192]. Proc Am Soc Clin Oncol 2005;23:239s.
27. Gumerlock PH, Kawaguchi T, Moisan LP, et al. Mechanisms of enhanced cytotoxicity from docetaxel© PS-341 combination in non-small cell lung carcinoma (NSCLC) [abstract 1214]. Proc Am Soc Clin Oncol 2002;21:304a.
28. Nawrocki S, Sweeney-Gotsch B, Takamori R, McConkey D. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004;3:59-70.
29. Pink M, Pien C, Ona V, Worland P, Adams J, Kauffman M. PS-341 enhances chemotherapeutic effect in human xenograft models [abstract 787]. Proc AACR 2002;43:158.
30. Canfield S, Zhu K, Williams S, McConkey D. Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther 2006;5: 2043-50.
31. Morris M, Beekman K, Kelly W, et al. Phase II Study of Bortezomib for castrate metastatic prostate Cancer (abstract 4633). Proc Am Soc Clin Oncol 2005;23:411S.
32. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22:2108-21
33. Siefker-Radtke A, Poulter V, Mathew P, Tu SM, Logothetis C, Papandreou C. Preliminary evidence of efficacy and tolerance for weekly intravenous bortezomib plus mitoxantrone in patients with advanced androgen-independent prostate cancer (AIPCa) [abstract 4567]. Proc Am Soc Clin Oncol 2005;23:394s.
34. Meluch A, Spigel D, Greco F, et al. Weekly docetaxel and bortezomib in the treatment of patients with advanced hormone refractory prostate cancer (HRPC): A Minnie Pearl Cancer Research Network phase II trial [abstract 4735]. Proc Am Soc Clin Oncol 2005;23:436s.
35. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 1999;17:3461-7.
36. Therasse P, Arbuck SG, Eisenhauer EA, et al.; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
37. Greco FA. Docetaxel (Taxotere) administered in weekly schedules. Semin Oncol 1999;26: 28-31.
38. Rizzo J, Garrison M, Molpus K, et al. A phase I and pharmacokinetic (PK) trial of docetaxel (D) administered weekly via 30 minute infusion to patients with solid tumors [abstract 827]. Proc Am Soc Clin Oncol 2000;19:212a.
39. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
40. Blaney SM, Bernstein M, Neville K, et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 2004;22:4804-9.
41. Hamilton AL, Eder JP, Pavlick AC, et al. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 2005; 23:6107-16.
42. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
43. Dy GK, Thomas JP, Wilding G, et al. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 2005;11:3410-6.
44. Aghajanian C, Soignet S, Dizon D, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
45. Messersmith WA, Baker SD, Lassiter L, et al. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 2006;12:1270-5.
46. Albanell J, Baselga J, Guix M, et al. Phase I study of bortezomib in combination with docetaxel in anthracycline-pretreated advanced breast cancer [abstract 63]. J Clin Oncol 2003;22:16.
47. Oudard S, Banu E, Beuzeboc P, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23:3343-51.
48. Beer T, Ryan C, Venner P, et al. Interim results from ASCENT: a double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC) [abstract 4516]. Proc Am Soc Clin Oncol 2005:382s.